137 related articles for article (PubMed ID: 28675691)
21. Case Report: Sustained Remission Due to PD-1-Inhibition in a Metastatic Melanoma Patient With Depleted B Cells.
Wulfken LM; Becker JC; Hayajneh R; Wagner AD; Schaper-Gerhardt K; Flatt N; Grimmelmann I; Gutzmer R
Front Immunol; 2021; 12():733961. PubMed ID: 34675925
[TBL] [Abstract][Full Text] [Related]
22. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
[TBL] [Abstract][Full Text] [Related]
23. Granulomatous/sarcoid-like reactions in the setting of programmed cell death-1 inhibition: a potential mimic of disease recurrence.
Hiraki T; Hatanaka M; Arimura A; Kawahira H; Kirishima M; Kitazono I; Horinouchi M; Higashi M; Kanekura T; Tanimoto A
J Cutan Pathol; 2020 Feb; 47(2):154-160. PubMed ID: 31437317
[TBL] [Abstract][Full Text] [Related]
24. PD-1 Antibody-induced Guillain-Barré Syndrome in a Patient with Metastatic Melanoma.
Schneiderbauer R; Schneiderbauer M; Wick W; Enk AH; Haenssle HA; Hassel JC
Acta Derm Venereol; 2017 Mar; 97(3):395-396. PubMed ID: 27868138
[No Abstract] [Full Text] [Related]
25. Programmed death-1 & its ligands: promising targets for cancer immunotherapy.
Shrimali RK; Janik JE; Abu-Eid R; Mkrtichyan M; Khleif SN
Immunotherapy; 2015; 7(7):777-92. PubMed ID: 26250412
[TBL] [Abstract][Full Text] [Related]
26. Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report.
Kwatra V; Karanth NV; Priyadarshana K; Charakidis M
J Med Case Rep; 2017 Mar; 11(1):73. PubMed ID: 28315636
[TBL] [Abstract][Full Text] [Related]
27. Resistance patterns to anti-PD-1 therapy in metastatic melanoma.
Ozgun A; Sondak VK; Markowitz J
Chin Clin Oncol; 2016 Dec; 5(6):75. PubMed ID: 27701871
[No Abstract] [Full Text] [Related]
28. A prolonged complete response in a patient with BRAF-mutated melanoma stage IV treated with the MEK1/2 inhibitor selumetinib (AZD6244).
Boers-Sonderen MJ; Desar IM; Blokx W; Timmer-Bonte JN; van Herpen CM
Anticancer Drugs; 2012 Aug; 23(7):761-4. PubMed ID: 22293660
[TBL] [Abstract][Full Text] [Related]
29. [A silent-growing and fast-killing melanoma in a teenager].
Uguen A; Talagas M; Quintin-Roué I; Abasq C; Coat C; Charles-Pétillon F; De Braekeleer M; Marcorelles P
Ann Pathol; 2012 Aug; 32(4):254-8. PubMed ID: 23010398
[TBL] [Abstract][Full Text] [Related]
30. Mitogen-Activated Protein Kinase Signaling Pathway in Cutaneous Melanoma: An Updated Review.
Acosta AM; Kadkol SS
Arch Pathol Lab Med; 2016 Nov; 140(11):1290-1296. PubMed ID: 27788045
[TBL] [Abstract][Full Text] [Related]
31. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
[TBL] [Abstract][Full Text] [Related]
32. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
[TBL] [Abstract][Full Text] [Related]
33. Pembrolizumab (Keytruda) for metastatic melanoma.
Med Lett Drugs Ther; 2014 Nov; 56(1455):e114-5. PubMed ID: 25538981
[No Abstract] [Full Text] [Related]
34. Pathogenetic Implications of BRAF Mutation Distribution in Stage IV Melanoma Patients.
Baiter M; Schuler G; Hartmann A; Schneider-Stock R; Heinzerling L
Dermatology; 2015; 231(2):127-33. PubMed ID: 26138035
[TBL] [Abstract][Full Text] [Related]
35. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
[TBL] [Abstract][Full Text] [Related]
36. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Weber JS; D'Angelo SP; Minor D; Hodi FS; Gutzmer R; Neyns B; Hoeller C; Khushalani NI; Miller WH; Lao CD; Linette GP; Thomas L; Lorigan P; Grossmann KF; Hassel JC; Maio M; Sznol M; Ascierto PA; Mohr P; Chmielowski B; Bryce A; Svane IM; Grob JJ; Krackhardt AM; Horak C; Lambert A; Yang AS; Larkin J
Lancet Oncol; 2015 Apr; 16(4):375-84. PubMed ID: 25795410
[TBL] [Abstract][Full Text] [Related]
37. Phenformin Inhibits Myeloid-Derived Suppressor Cells and Enhances the Anti-Tumor Activity of PD-1 Blockade in Melanoma.
Kim SH; Li M; Trousil S; Zhang Y; Pasca di Magliano M; Swanson KD; Zheng B
J Invest Dermatol; 2017 Aug; 137(8):1740-1748. PubMed ID: 28433543
[TBL] [Abstract][Full Text] [Related]
38. Usefulness of immunocytochemistry for the detection of the BRAF(V600E) mutation in circulating tumor cells from metastatic melanoma patients.
Hofman V; Ilie M; Long-Mira E; Giacchero D; Butori C; Dadone B; Selva E; Tanga V; Passeron T; Poissonnet G; Emile JF; Lacour JP; Bahadoran P; Hofman P
J Invest Dermatol; 2013 May; 133(5):1378-81. PubMed ID: 23303445
[No Abstract] [Full Text] [Related]
39. TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
Chauvin JM; Pagliano O; Fourcade J; Sun Z; Wang H; Sander C; Kirkwood JM; Chen TH; Maurer M; Korman AJ; Zarour HM
J Clin Invest; 2015 May; 125(5):2046-58. PubMed ID: 25866972
[TBL] [Abstract][Full Text] [Related]
40. Multiple BRAF Wild-Type Melanomas During Dabrafenib Treatment for Metastatic BRAF-Mutant Melanoma.
Carrera C; Puig-Butillè JA; Tell-Marti G; García A; Badenas C; Alós L; Puig S; Malvehy J
JAMA Dermatol; 2015 May; 151(5):544-8. PubMed ID: 25651238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
